METTL7A functions as a tumor suppressor in colorectal cancer by binding to SREBP1 and SCAP, inhibiting SREBP1 nuclear translocation and reducing cholesterol synthesis.
METTL7A inhibits colorectal cancer progression by suppressing the SREBP1-mediated cholesterol synthesis pathway.
This study provides valuable insights into the role of METTL7A in CRC and its impact on metabolic reprogramming, particularly cholesterol synthesis, and identifies METTL7A as a potential therapeutic target of CRC.
Li et al. (Mon,) conducted a other in Colorectal cancer. METTL7A vs. Control was evaluated on Tumor progression and cholesterol synthesis. METTL7A functions as a tumor suppressor in colorectal cancer by binding to SREBP1 and SCAP, inhibiting SREBP1 nuclear translocation and reducing cholesterol synthesis.